PubMed COVID-19 Clinical Care

No abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been associated with a wide range of "long COVID" neurological symptoms. However, the mechanisms governing SARS-CoV-2

The design of protein interaction inhibitors is a promising approach to address aberrant protein interactions that cause disease. One strategy in designing inhibitors is to use peptidomimetic scaffolds that mimic the natural interaction interface. A

Since the COVID-19 health crisis, telemedicine has received a lot of attention around the world. Following attempts to set up a telemedicine system, in particular teleconsultation and teleexpertise, which proved inconclusive in Burkina, we have seen

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus pandemic in 2019, commonly causes hepatic dysfunction. Liver injury ranges from mildly elevated liver enzymes to fulminant liver failure

Herpes simplex virus type 2 (HSV-2) is a common cause of infection, which is usually self-limited and asymptomatic. A 71-year-old patient with HSV-2 primo-infection developed acute hepatitis and secondary hemophagocytic lymphohistiocytosis. The

CONCLUSIONS: Of the comorbidities studied, DM and cIHD together with COVID-19 elevated the risk of in-hospital lethality significantly. Within the acute in-hospital complications, pneumonia with respiratory failure and acute renal failure showed the

The anticipated increase in the influx of plastic waste into aquatic environments has propelled the identification and elimination of plastic waste into the global agenda. The plastics sector generates a significant volume of materials, which, due to

The resolution of SARS-CoV-2 replication hinges on cell-mediated immunity, wherein CD8^(+) T cells play a vital role. Nonetheless, the characterization of the specificity and TCR composition of CD8^(+) T cells targeting non-spike protein of SARS-CoV

CONCLUSIONS: LT patients present the lowest response to the SARS-CoV-2 vaccine. In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level.